SunTrust Banks Analysts Give La Jolla Pharmaceutical (LJPC) a $45.00 Price Target

SunTrust Banks set a $45.00 target price on La Jolla Pharmaceutical (NASDAQ:LJPC) in a research note released on Thursday morning, The Fly reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on LJPC. HC Wainwright cut their target price on La Jolla Pharmaceutical to $53.00 and set a buy rating on the stock in a report on Friday, July 27th. Zacks Investment Research raised La Jolla Pharmaceutical from a sell rating to a hold rating in a research report on Tuesday, April 17th. BidaskClub raised La Jolla Pharmaceutical from a hold rating to a buy rating in a research report on Tuesday, July 24th. ValuEngine lowered La Jolla Pharmaceutical from a sell rating to a strong sell rating in a research report on Thursday, April 19th. Finally, Chardan Capital reaffirmed a buy rating and set a $115.00 target price on shares of La Jolla Pharmaceutical in a research report on Monday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company has an average rating of Hold and an average price target of $50.00.

Shares of La Jolla Pharmaceutical stock traded down $1.27 on Thursday, reaching $23.20. 1,472,970 shares of the company’s stock were exchanged, compared to its average volume of 538,159. La Jolla Pharmaceutical has a 52 week low of $22.68 and a 52 week high of $41.36.



La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.07). The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $2.48 million. sell-side analysts forecast that La Jolla Pharmaceutical will post -7.44 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter valued at about $134,000. Silvant Capital Management LLC bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter valued at about $189,000. MetLife Investment Advisors LLC bought a new stake in shares of La Jolla Pharmaceutical during the 4th quarter valued at about $276,000. WINTON GROUP Ltd bought a new stake in shares of La Jolla Pharmaceutical during the 1st quarter valued at about $276,000. Finally, First Midwest Bank Trust Division bought a new stake in shares of La Jolla Pharmaceutical during the 2nd quarter valued at about $279,000.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Further Reading: Penny Stocks, Risk and Reward Factors

The Fly

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply